(19)
(11) EP 1 722 229 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.11.2009 Bulletin 2009/48

(45) Mention of the grant of the patent:
07.10.2009 Bulletin 2009/41

(21) Application number: 05701698.2

(22) Date of filing: 03.02.2005
(51) International Patent Classification (IPC): 
G01N 33/564(2006.01)
C07K 14/705(2006.01)
 G01N 33/566(2006.01)
(86) International application number:
PCT/ES2005/000046
(87) International publication number:
WO 2005/076000 (18.08.2005 Gazette 2005/33)

(54)

METHOD OF ASSESSING RISK OF AND PREDISPOSITION TO THE DEVELOPMENT OF A PATHOLOGY RELATED TO THE PRESENCE OF ANTI-EPCR ANTIBODIES

VERFAHREN ZUR BEURTEILUNG DER GEFAHR UND VERANLAGUNG, EINE MIT DEM VORLIEGEN VON ANTI-EPCR-ANTIKÖRPERN VERBUNDENE SYMPTOMATIK ZU ENTWICKELN

METHODE D'EVALUATION DU RISQUE ET DE LA PREDISPOSITION A DEVELOPPER UNE PATHOLOGIE ASSOCIEE A LA PRESENCE D'AUTOANTICORPS DU EPCR

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
Designated Extension States:
AL BA HR LV MK YU

(30) Priority: 06.02.2004 ES 200400269

(43) Date of publication of application:
15.11.2006 Bulletin 2006/46

(73) Proprietor: Proyecto de Biomedicina Cima, S.L.
31180 Zizur Mayor - Navarra (ES)

(72) Inventors:
  • HERMIDA SANTOS, José
    31008 Pamplona (Navarra) (ES)
  • MONTES DIAZ, Ramon
    31008 Pamplona (Navarra) (ES)
  • HURTADO LINARES, Verónica
    31008 Pamplona (Navarra) (ES)

(74) Representative: ABG Patentes, S.L. 
Avenida de Burgos 16D Edificio Euromor
28036 Madrid
28036 Madrid (ES)


(56) References cited: : 
EP-A1- 0 600 088
US-B2- 6 617 145
 US-A- 6 037 450
   
  • OOSTING J.D. ET AL: 'Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?.' BLOOD. vol. 81, no. 10, May 1993, pages 2618 - 2625, XP008070727
  • GU J.M. ET AL: 'Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality.' THE JOURNAL OF BIOLOGICAL CHEMISTRY. vol. 277, no. 45, November 2002, pages 43335 - 43343, XP008042848
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).